156 related articles for article (PubMed ID: 38267108)
21. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
[No Abstract] [Full Text] [Related]
22. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
[TBL] [Abstract][Full Text] [Related]
23. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Martynyuk TV; Aleevskaya AM
Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
[TBL] [Abstract][Full Text] [Related]
24. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
Martynyuk TV; Nakonechnikov SN; Chazova IY
Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
[TBL] [Abstract][Full Text] [Related]
25. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.
Herbert S; Gin-Sing W; Howard L; Tulloh RMR
Heart Lung Circ; 2017 Oct; 26(10):1113-1116. PubMed ID: 28237536
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R; Delcroix M; Galié N; Jansa P; Mehta S; Pulido T; Rubin L; Sastry BKS; Simonneau G; Sitbon O; Torbicki A; Boyanova N; Chamitava L; Stein C; Channick RN
Adv Ther; 2022 Sep; 39(9):4374-4390. PubMed ID: 35819570
[TBL] [Abstract][Full Text] [Related]
27. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
28. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
Dhillon S
Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
[TBL] [Abstract][Full Text] [Related]
30. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
31. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
32. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
[TBL] [Abstract][Full Text] [Related]
33. A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.
Okour M; Puri A; Chen G; Port K; Berni A; Khindri S; Schneider I; Tenero D
Clin Ther; 2019 Jun; 41(6):1110-1127. PubMed ID: 31060740
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension.
Dong W; Zhang Z; Chu M; Gu P; Hu M; Liu L; Huang J; Zhang R
Front Pharmacol; 2023; 14():1122866. PubMed ID: 37637431
[No Abstract] [Full Text] [Related]
36. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
37. Macitentan in the treatment of pulmonary arterial hypertension.
Zebadúa R; Hernández-Pérez AP; García A; Zayas N; Sandoval J; López J; Pulido T
Future Cardiol; 2021 Jan; 17(1):49-58. PubMed ID: 32677463
[TBL] [Abstract][Full Text] [Related]
38. Development of macitentan for the treatment of pulmonary arterial hypertension.
Selej M; Romero AJ; Channick RN; Clozel M
Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
[TBL] [Abstract][Full Text] [Related]
39. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
40. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
